ArticleTranslational cancer research2019

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?

Andrea Bianco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.